Molecules can block breast cancer's ability to spread

Key points
- Researchers have identified a specific group of microRNA molecules that are responsible for controlling genes that cause breast cancer metastasis.
- MicroRNAs are known to inhibit the activity of entire sets of genes associated with cancer metastasis Ц a process that leads to the majority of cancer-related deaths.
- The researchers examined human breast cancer cells with strong metastatic ability and found that the cells had lost large numbers of three different microRNA molecules.
- In addition, the researchers looked at breast cancer patients and discovered that those with tumors that had lost these molecules were much more likely to suffer from cancer metastasis to the lung and bone.
Researchers have identified a specific group of microRNA molecules that are responsible for controlling genes that cause breast cancer metastasis. The study, led by scientists at Memorial Sloan-Kettering Cancer Center (MSKCC), appears in the January 10, 2008, issue of Nature.
MicroRNAs are known to inhibit the activity of entire sets of genes associated with cancer metastasis Ц a process that leads to the majority of cancer-related deaths. The new work explains how the loss of certain microRNAs allows cancer cells to migrate through organ tissue and to grow more rapidly.
The researchers examined human breast cancer cells with strong metastatic ability and found that the cells had lost large numbers of three different microRNA molecules. Conversely, when researchers put those molecules back into human breast cancer tumors in mice, the tumors lost their ability to spread.
In addition, the researchers looked at breast cancer patients and discovered that those with tumors that had lost these molecules were much more likely to suffer from cancer metastasis to the lung and bone.
УThe identification of molecules that inhibit a cellТs metastatic potential may help guide clinical decision-making in the future by enabling oncologists to more accurately identify patients at highest risk for metastatic relapse,Ф said the studyТs lead author Sohail Tavazoie, MD, PhD, a postdoctoral fellow in the Oncology-Hematology Fellowship program at MSKCC.
In further analyzing one of these microRNAs, called miR-335, investigators found that miR-335 works by suppressing certain genes that are associated with human metastasis, particularly SOX4, which acts as a transcription factor (meaning that it regulates a group of genes responsible for cell development and migration), and tenascin-C, which functions outside the cell in what is called the extracellular matrix and is implicated in cell migration.
УWe now have a better understanding of the role this molecular pathway plays as a suppressor of breast cancerТs ability to spread to the lung and bone, and we have identified the genes involved in that process. These findings may enhance our ability to come up with more effective drugs to prevent or treat cancer metastasis,Ф said Joan Massaguй, PhD, Chair of the Cancer Biology and Genetics Program at MSKCC, a Howard Hughes Medical Institute Investigator, and the studyТs senior author.
###
The study was co-authored by William L. Gerald, MD, PhD, a surgical pathologist and member of the Human Oncology and Pathogenesis Program at MSKCC, and by members of Dr. MassaguйТs laboratory, including Claudio Alarcуn, graduate student; Thordur Oskarsson, PhD, research fellow; David Padua, graduate student; Qiongqing Wang, PhD, research fellow; and Paula D. Bos, graduate student.
The research was funded by grants from the National Institutes of Health, the Hearst Foundation, the Kleberg Foundation, and the Olson Foundation, and a Clinical Scholars Award.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNYU nursing study examines obesity in relation to breast cancer related lymphedema
Each year, about 1.38 million women worldwide are diagnosed with breast cancer. Advances in treatment have facilitated a 90% five-year survival rate among those treated. Given the increased rate and length of survival…
18 December 2015
NewsNeoadjuvant use of pertuzumab in HER2-positive breast cancer
Pertuzumab (trade name: Perjeta) is approved for two therapeutic indications. Its use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable…
4 December 2015
NewsPotential new therapy for triple-negative breast cancer shows promise in lab studies
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult to treat and aggressive form of the disease. In a recent study…
28 October 2015




